InvestorsHub Logo
Followers 43
Posts 4314
Boards Moderated 0
Alias Born 09/01/2017

Re: H2R post# 491152

Wednesday, 06/29/2022 1:50:37 PM

Wednesday, June 29, 2022 1:50:37 PM

Post# of 704670
Taking a couple of steps back to get the macro perspective instead of rolling around in the noise, the following can be noted:

1) overall strengthened position for nwbo
— TL results are positive & breakthrough
— DCVax safest & extremely QoL positive
— only GBM/rGBM w/long term survivors
— patients becoming aware & requesting
— DCVax production & treatment in UK
— revenue from UK & compass’n ramping
— UK support high & approval very likely
— FDA validated & sponsors ext controls
— OS gold std (pdf = not immunotherapy)
— peer reviewed journal pub will happen
— approvals are extremely likely
— DCVax effectively SOC in combo trials
— There Is No Alternative in near future

2) primary negatives
— continued target of attacks
— investors patience extremely taxed
— narratives of looming dilutions
— BPs may be threatened in cancer biz
— endless FUD
— nonzero risk of non approvals

3) remember 1)
— especially only long term survivorship


Bottom line imo, very frustrating waiting for ultimate widespread patient QoL and life extension success, and investor ROI rewards!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News